{"schema_version":"secwatch.filing_event.v1","accession":"0001570562-23-000119","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2023-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.570762+00:00","generated_at":"2026-06-07T09:49:56.221704+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Evolus signs exclusive deal with Symatese for four dermal fillers in Europe; issues 610,000 shares","bullets":["Exclusive rights to distribute Lift, Smooth, Sculpt, and Lips fillers under Estyme® brand in 50 European countries.","Consideration includes 610,000 common shares to Symatese and up to €3.1M in milestone payments.","European regulatory approvals expected H2 2024; commercialization targeted for 2025.","No material impact on 2025 profitability target; company to pre-announce Q4/FY 2023 results and 2024 guidance in January.","Evolus licenses Nuceiva® to Symatese for France; sub-licenses Estyme® distribution in France to Symatese subsidiary."],"urls":{"canonical":"https://secwatch.observer/filing/0001570562-23-000119","json":"https://secwatch.observer/filing/0001570562-23-000119.json","markdown":"https://secwatch.observer/filing/0001570562-23-000119.md","text":"https://secwatch.observer/filing/0001570562-23-000119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000119/0001570562-23-000119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000119/eols-20231220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:49:56.221704+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"95de0803c3f48446c01846d6a7b07db1d7f843c6","claim":"Evolus, Inc. entered into License, Supply and Distribution Agreement with Symatese Aesthetics S.A.S. valued at 610,000 shares of the Company’s common stock (effective 2023-12-20).","evidence_excerpt":"On December 20, 2023, Evolus Pharma B.V. (“Evolus Europe”), a wholly owned subsidiary of Evolus, Inc. (the “Company”) and Symatese Aesthetics S.A.S. (“Symatese”), entered into a License, Supply and Distribution Agreement (the “Agreement”), pursuant to which Symatese granted to Evolus Europe an exclusive right to commercialize and distribute four dermal filler product candidates","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056223000119/0001570562-23-000119-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Symatese Aesthetics S.A.S."},{"label":"Value","value":"610,000 shares of the Company’s common stock"},{"label":"Effective","value":"2023-12-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}